paclitaxel (SMS001) / ToLymph - LARVOL DELTA

An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=42 | Recruiting | Sponsor: ToLymph Inc. | Trial primary completion date: Oct 2025 ➔ Nov 2026

Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor